Business intelligence
for the Lab Diagnostics industry
Already a Subscriber? Log in Here
We offer four monthly reports, each focused on the industry from a unique angle, covering science & technology, compliance, business, and legislation & regulations.
Diagnostic Testing & Emerging Technologies
Keeps you up-to-date on new diagnostic tests, testing trends and opportunities, and emerging test technologies
Lab Compliance Advisor
Offers practical, “what-to-do” and “how-to-do-it” help to comply with the latest state and federal laws, rules, and regulations that affect your diagnostic lab or pathology practice
Laboratory Industry Report
Keeps you up-to-date on lab business and competitive strategy, market trends and opportunities, and M&A and investment activity in today’s diagnostic lab industry
National Lab Reporter
Keeps you up-to-date on federal and state laws, regulations, new legislation, and court cases that affect your diagnostic lab or pathology practice
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
Weekly Enforcement Report: Drug Testing Fraud Dominates
Last week’s three key cases included two involving drug testing that was either medically unnecessary, or not provided at all.
Proposed Rule Would Water Down CLIA Requirements for Lab Directors and Testing Personnel
While the rule has not yet been approved, if it is, nursing degrees would be considered the equivalent of biological science degrees.
Quest Expands into MRD Liquid Biopsy with Haystack Oncology Buy
The acquisition of the Johns Hopkins spin out and its liquid biopsy ctDNA test will significantly strengthen Quest’s oncology offerings.
New Bill Would Guarantee Medicare Coverage of Newly Approved Breakthrough Devices
Congress brings back controversial Trump plan scrapped by the Biden administration.
Adapting to the New Normal: Navigating the Intersection of Healthcare and Economics in a Distributed Healthcare Delivery Model
In this session, learn key aspects of the data laboratories hold and potential uses for that data to strengthen laboratory financial health.
Sales and Marketing—Beyond COVID
Learn numerous proven field strategies and tactics to help laboratory sales reps achieve success in today's challenging environment.
CDC Calls Continued Rise in Cases of STIs “Alarming”
Health inequities and disrupted STI testing and care during the pandemic continued to contribute to a rise in cases in 2021.
Medicare Expands Coverage of Molecular Cancer Screening Tests
In terms of Medicare coverage, 2023 is shaping up to be a fruitful year—here are five of the most significant approvals so far.
Growth of Medical & Consumer Debt Poses New Challenges for Collections
Increasing medical and consumer debt is likely to get worse, meaning billing and collections may get even tougher for labs.
Hostile Regulatory Environment Further Chills Diagnostics Market
The biggest story in M&A dealmaking continues to be the deal that’s being undone—Illumina’s acquisition of GRAIL.
A Timeline of 2023 Lab Company Layoffs So Far
The wave of layoffs, which began last year with the declines in COVID-19 testing sales, has gathered momentum in 2023.
Bill Would Require Medicare to Cover New Breakthrough Devices for at Least 4 Years
The bill is designed to provide Medicare patients faster access to innovative technology approved by the FDA.
Lab Companies Team with Nonprofits on Test Development, Access, & Awareness
April was among the busiest months, in recent memory, in terms of both deal volume and significance in the diagnostics industry.
